Research analysts covering Polyrizon.
Recent press releases and 8-K filings for PLRZ.
Polyrizon to Explore Revenue-Generating Real Asset Opportunities
PLRZ
New Projects/Investments
Revenue Acceleration/Inflection
- Polyrizon Ltd. (PLRZ) announced on December 29, 2025, that its Board of Directors has decided to explore investment opportunities in revenue-generating real assets.
- This strategic initiative is being pursued by leveraging the Company's strong cash position and debt-free balance sheet.
- The Company remains fully committed to advancing its core medical device activities, including product development and regulatory progress for products such as PL-14, PL-16, and the Trap & Target platform.
- The aim of exploring these new investments is to efficiently utilize resources to accelerate growth and deliver long-term shareholder value.
Dec 29, 2025, 12:59 PM
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
PLRZ
New Projects/Investments
Product Launch
- Polyrizon Ltd. completed a pre-submission meeting with the U.S. Food and Drug Administration (FDA) on December 8, 2025, regarding its PL-14 Allergy Blocker Nasal Spray.
- During the meeting, Polyrizon presented its general development program plan, including manufacturing processes, quality controls, and the clinical development strategy, with clinical trials for PL-14 expected to commence in 2026.
- The company considers this meeting a significant milestone, providing early regulatory alignment and clarity to efficiently advance the PL-14 program.
- The global allergen blocker market is projected to reach $210 million by 2033.
Dec 8, 2025, 2:00 PM
Polyrizon Ltd. Announces Registered Direct Offering
PLRZ
New Projects/Investments
M&A
- Polyrizon Ltd. entered into a securities purchase agreement on December 5, 2025, for a registered direct offering of 552,269 ordinary shares at a purchase price of $9.00 per share.
- The offering is expected to generate approximately $4.97 million in aggregate gross proceeds.
- The net proceeds from the offering will be used for general corporate purposes, including financing operations, capital expenditures, business development, technology development, and pursuing strategic opportunities such as acquisitions.
- The company agreed to pay Aegis Capital Corp a financial advisory fee of $250,000.
Dec 5, 2025, 11:52 AM
Polyrizon Completes Manufacturing Upscaling Milestone for Nasal Spray Platform
PLRZ
New Projects/Investments
- Polyrizon Ltd. (PLRZ) announced on December 2, 2025, the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform.
- This achievement involved transitioning from small-batch laboratory production to a larger-scale, controlled manufacturing run, which validated key parameters of the PL-14 formulation.
- The manufacturing process is now set to support the clinical trial material (CTM) needed for Polyrizon’s clinical trial, which is expected to commence in 2026.
Dec 2, 2025, 12:57 PM
Polyrizon Announces Positive Pre-Clinical Results for PL-14
PLRZ
Product Launch
New Projects/Investments
- Polyrizon Ltd. announced positive pre-clinical results for its PL-14 Allergy Blocker formulation, which is designed to prevent allergen penetration.
- The study demonstrated that PL-14 effectively limited allergen diffusion, with only 1.07% of the allergen passing through after one hour and 13.6% after four hours, even when exposed to allergen loads estimated to be tens of times higher than typical real-world levels.
- The company plans to initiate clinical studies for PL-14 and other candidates within its Capture & Contain (C&C) platform.
- The Allergy Immunotherapy market is projected to grow from $1.9 billion in 2025 to $4.2 billion by 2035, expanding at a 7.9% Compound Annual Growth Rate (CAGR).
Oct 6, 2025, 12:36 PM
Polyrizon Ltd. Reports Q2 2025 Financials, Private Placement, and Nasdaq Compliance
PLRZ
Earnings
New Projects/Investments
Delisting/Listing Issues
- For the six months ended June 30, 2025, Polyrizon Ltd. reported a net loss of $(177) thousand and held cash and cash equivalents of $15,828 thousand as of June 30, 2025.
- The company believes its existing cash and cash equivalents will be sufficient to fund its operations until the end of 2029.
- Net cash provided by financing activities for the six months ended June 30, 2025, was $15,097 thousand, primarily due to a $17.0 million private placement closed in April 2025.
- Polyrizon Ltd. effected a 1-for-250 reverse share split on May 23, 2025, and formally regained compliance with Nasdaq's Minimum Bid Price Rule on August 13, 2025.
Sep 17, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more